$UFPT (+1,91 %)

UFP Technologies increased its net income in the third quarter of 2026 by 25.8 percent year-over-year to $20.6 million.

Quarterly revenue rose 11.6 percent to $172.4 million.

Adjusted EPS of $2.88 and revenue exceeded analysts’ expectations.

A conference call is scheduled for November 4 to discuss the results in more detail.

Revenue and Earnings Grow in the Third Quarter

The contract developer and manufacturer, which specializes in customized products and solutions for medical technology and sterile packaging, posted a net profit of $20.6 million for the quarter ending September 30, 2026. In the same period last year, the figure was $16.4 million. Revenue rose from $154.6 million to $172.4 million.

Earnings per diluted
share under U.S. Generally Accepted Accounting Principles (GAAP) was $2.64; on an adjusted basis, UFP Technologies reported $2.88. This means that adjusted EPS exceeded the analyst estimate of $2.54 cited in the available financial data. The company’s revenue of $172.4 million also exceeded expectations of $165.35 million

Nine-Month Results Confirm Growth

For the first nine months of 2026, UFP Technologies reported net income of $59.0 million, up 16.2 percent from the same period last year. Revenue totaled $500.6 million. Comparative figures for nine-month revenue are not included in the available data.

Analyst Assessment: The quarter shows disproportionately strong growth in net income relative to revenue. This points to an improvement in earnings performance; however, the published metrics alone do not reveal which factors—such as costs, product mix, or prices—were responsible for this. For investors, the fact that earnings exceeded expectations by a factor of two represents a positive earnings boost, while the conference call is likely to provide additional insights into the sustainability of this growth.

$UFPT (+1,91 %)

The company reported strong preliminary results yesterday.

The earnings call will take place today at 2:30 p.m. CET.

*UFP Technologies reported a net income of $20.9 million for the second quarter, an increase of 21.4 percent.

* Revenue climbed 15.1 percent to $174 million.

* The gross margin expanded to 29.3 percent, up from 28.8 percent in the same quarter last year.

* Operating income rose by 15.5 percent to $28.1 million.

* Revenue from the top 5 customers grew by 14.7 percent; the rest of the medtech business grew by 19.7 percent, while the non-medical segment remained unchanged.

$UFPT (+1,91 %)

I remain invested here too.

Strong demand push in new programs

• From 4 new customer programs were 3 were asked to double their production capacity.
• This indicates surprisingly high demand and accelerated scaling.

Second half of the year expected to pick up significantly

• Management expects a clear ramp-up in H2as several major programs enter the ramp-up phase phase.
• MedTech programs in particular are driving growth.

Capacity expansion already underway

• UFP is investing in additional machines, automation and production spaceto enable the requested doubling of capacity.
• Focus on efficiency and margin stability despite expansion.

Strategic importance of the new programs

• The programs are among key products for major MedTech customers.
• Long-term sales quality: High visibility, multi-year terms, high margins.

Overall message

• Short-term: Expenses due to capacity expansion.
• Medium-term: Significantly higher sales level and margin leverageas soon as the programs are running at full capacity.

@Simpson

Hey, GQ crew ✌️

My first post since I got kicked out about 4 weeks ago—who would’ve thought that showing solidarity with one of the members (@Klein-Anleger ) would lead to a ban so quickly? But getquin’s generosity was so BIG (and, most importantly, “on a trial basis”) that they graciously let me back into the holy grail of the GQ community 😉

So guys, learn from my mistakes: The leniency here isn’t an “infinite money” glitch! Save your solidarity for later, keep your support for other members at zero, and most importantly 🚨: No sneaky advertising for alternative financial platforms like “Cisdord” 😉😂.

Sorry, that little dig after four weeks away was a must 🤝

But joking aside…

⏳The first three months of 2026 have passed. Time for a brief interim assessment of the current status of my portfolio rebuild.

Before I started rebuilding my portfolio, I naturally thought about what strategy I wanted to pursue in the coming months and years—especially with regard to stock selection and weighting.

To be honest, my original plan was to maintain a portfolio with a maximum of 20 stocks. As things progressed, however, I realized that it probably wouldn’t stay at 20—the number is more likely to rise to around 30 positions (+/-)—

♟️My Focus & Strategy:

To put it simply: The clear focus is on growth 🚀. Dividends play a rather secondary role here. Here, I’ll show you my shopping list—or rather, what my portfolio should look like in the future. The stocks I’ve already bought are marked with a green checkmark; those without a checkmark are ones I’m still waiting on ⏳

🤖TECH:

• AMAZON $AMZN (+1,98 %) ✅
• MICROSOFT $MSFT (+1,13 %) ✅
• CROWDSTRIKE $CRWD (+0,15 %) ✅
• SYNOPSYS $SNPS (+3,34 %) ✅
• INTUIT $INTU (-2,1 %) ✅
• CONSTELLATION SOFTWARE $CSU (+0,45 %) ✅
• SERVICENOW $NOW (+2,23 %) ✅
• ALPHABET $GOOGL (+2,52 %)
• NVIDIA $NVDA (+3,8 %)
• ASML $ASML (+5,23 %)
• MONOLITHIC POWER SYSTEMS $MPWR (+5,53 %)
• ARISTA NETWORKS $ANET (+8,23 %)
• KEYENCE $6861 (+2,14 %) ✅
• TSMC $TSM (+6,69 %)
• MARUWA $5344 (+3,62 %)
• LASERTEC CORP $6920 (+11,08 %)
• NETCOMPANY $NETC (-1,34 %) ✅
• CELLEBRITE DI $CLBT (+1,75 %) ✅

🏦💸FINANCE:

• SOFI TECHNOLOGIES $SOFI (+2,98 %) ✅
• S&P GLOBAL $SPGI (+0,14 %) ✅
• VISA $V (+1,12 %) ✅
• MUNICH RE $MUV2 (-3,69 %) ✅
• GERMAN STOCK EXCHANGE $DB1 (-1,95 %) ✅
• PARTNERS GROUP $PGHN (+0,59 %) ✅
• BROOKFIELD CORP $BN (+0,43 %) ✅
• HOULIHAN LOKEY $HLI (-0,23 %) ✅
• BROADRIDGE $BR (-1,13 %) ✅
• CBOE GLOBAL MARKETS $CBOE (+0,92 %)

🏥🩻HEALTHCARE:

• NOVO NORDISK $NOVO B (+0,94 %) ✅
• INTUITIVE SURGICAL $ISRG (-1,32 %)
• STRYKER $SYK (-1,22 %)
• BOSTON $BSX (-2,93 %)
• CATALYST PHARM $CPRX

🏭🏗️INDUSTRY & OTHER:

• WASTE MANAGEMENT $WM (-0,86 %) ✅
• GRAB HOLDINGS $GRAB (-0,53 %) ✅
• CINTAS $CTAS (-1,1 %) ✅
• MonotaRO $3064 ✅
• ITOCHU $8001 (-2,66 %) ✅
• HERMES $RMS (-0,48 %) ✅
• MERCADOLIBRE $MELI (-0,32 %) ✅

————————————————————————

Here is my expanded watchlist:

IN THE TECH SECTOR:

RAMBUS $RMBS (+7,71 %) , QNITY ELECTRONICS $Q (+6,36 %) ,

INNODATA $INOD (-12,19 %) , NETFLIX $NFLX (-1,34 %) ,

VERTIV $VRT (+4,29 %) , PALANTIR $PLTR (+5,57 %) , VAT GROUP $VACN (+0,45 %) , BROADCOM $AVGO (+1,41 %) , AMADEUS IT $AMS (+2,35 %) , DISCO CORP $6146 (+9,68 %) , A10 NETWORKS $ATEN (+8,59 %) , RORZE $6323 , CAMTEK $CAMT (+6,55 %)

FINANCE:

APOLLO GLOBAL $APO (+0,26 %) / BLACKSTONE $BX (+0,47 %) , ALLIANZ $ALV (-2,56 %) , FIRSTCASH $FCFS (-0,25 %) , BLACKROCK $BLK (+1,49 %) SKYWARD SPECIALTY INSURANCE $SKWD , VERISK ANALYTICS $VRSK (-3,42 %) PRIMERICA $PRI (+1,56 %) , ERIE INDEMNITY $ERIE (-3,92 %) , MAREX GROUP $MRX , BGC GROUP $BGC (+1,08 %)

HEALTHCARE:

MERIT MEDICAL SYSTEMS $MMSI (-1,88 %) , REGENERON PHARM $REGN (+1,89 %) , UFP TECHNOLOGIES $UFPT (+1,91 %) , COLLEGIUM PHARM $COLL (-3,56 %) , LIGAND PHARM $LGND (+3 %) , HOYA CORP $7741 (-0,77 %) , SHIONOGI $4507 (-0,63 %) , IRADIMED $IRMD (+1,97 %)

REST:

MISUMI GROUP $9962 (+0,47 %) , KANEMATSU $8020 (+0,8 %) , APPLIED INDUSTRIAL TECH $AIT (+1,6 %) , BADGER METER $BMI (+0,18 %) , CEMENT ROADSTONE HOLDING $CRH (+0,02 %) , KADANT $KAI (-1,5 %) , INTERTEK GROUP $ITRK (+0,74 %) , IDEX CORP $IEX (+2,72 %) , ORLA MINING $OLA , NEWMARKET CORP $NEU (+0,81 %) , ROTORK $ROR (+0,42 %) , POWER INTEGRATION $POWI (+4,58 %) , LINDE $LIN (-1,49 %) , GAZTRANSPORT & TECHNIGAZ $GTT (+0,28 %)

This isn’t my final stock selection or watchlist yet. Of course, changes can always happen—for example, if the @Tenbagger2024 continues to introduce such hidden gems 🙏🏽🧐

————————————————————————

What should the sector/country allocation look like?

Let’s start with the “desired”

🌍country allocation:

🇺🇸🇨🇦USA ~60%

🇪🇺EUROPE ~20%

🇯🇵 JAPAN/ASIA ~15%

Remaining ~5%

Sector weightings should be as follows:

💻 TECHNOLOGY: ~30–35%

💸FINANCE: ~20–25%

🏥HEALTHCARE: ~10–15%

🏭INDUSTRY: ~10–15%

REMAINING: ~5–10%

So, what’s happened since the start of the year?

Of course, there were no sales 😬

There were a few purchases where I had a hand in the decision.

JANUARY PURCHASES

$INTU (-2,1 %)
$GRAB (-0,53 %)
$NOW (+2,23 %)
$MSFT (+1,13 %)

FEBRUARY PURCHASES

$NOW (+2,23 %)
$INTU (-2,1 %)
$SPGI (+0,14 %)
$SNPS (+3,34 %)
$CSU (+0,45 %)
$SOFI (+2,98 %)
$CRWD (+0,15 %)

MARCH PURCHASES

$MUV2 (-3,69 %)
$3064
$8001 (-2,66 %)
$6861 (+2,14 %)
$DB1 (-1,95 %)
$V (+1,12 %)
$HLI (-0,23 %)
$MSFT (+1,13 %)
$CTAS (-1,1 %)
$MELI (-0,32 %)
$BN (+0,43 %)
$PGHN (+0,59 %)
$BR (-1,13 %)

Given the global political situation—especially because of that 🍊 in the White House, whose tweets cause more tsunamis 🌊than actual natural disasters—and the current drawdown in the S&P 500 (which is actually working out great for me right now and bringing me a lot of joy 🤩), I’m consequently in the red on some of my purchases so far 💦🫧.

But hey, we’re investing for the long term, after all, right? So, taking it easy, keeping it chill 🥱 I’ll most likely hold off on making any more purchases for the time being over the next few days or weeks, park my cash elsewhere or put it in a money market account, and wait to see where the market settles or wait for it to stabilize.

What do you guys have on your watchlist?

Are you sitting on the sidelines right now, or how are you handling the current situation?

@Get_Rich_or_Die_Tryin
@Tenbagger2024
@Max095 And, of course, all the other members

Okay, that’s enough for now 😂

That’s all from me for now ✌️

Your Stock Master

Just about managed to say goodbye 😁

Top3 : $LMT (-1,2 %)
$NFLX (-1,34 %)
$IESC (+9,67 %)

Flop3 : $CMG (-1,04 %)
$UFPT (+1,91 %)
$HIMS (+9,93 %)

$UFPT (+1,91 %)

Hello friends,

Today I would like to remind you once again of a king of points from my portfolio.

I already presented this share 2 months ago.

Today's reminder is for the following reason:

@TomTurboInvest

The stock is right at a short-term resistance level. A breakout above 250 USD would be a bullish signal.

📉 Momentum & volume

• Daily volume: 175,131 shares - increased, indicates active interest
• P/E RATIO: 19.29 - Moderate for a growth-oriented MedTech company

Momentum has a positive effect, as rising price + solid volume occur together.

🧭 Possible scenarios

Bullish case

• Breakout above 250 USD → Target zone 265-275 USD, later 290 USD
• Supported by strong long-term uptrend

Neutral / range case

• Sideways between 243-250 USD
• Consolidation after the recent rise

Bearish Case

• Break below 243 USD → Setback direction 230-235 USD
• Only below 230 USD the trend would become structurally weaker

📝 Overall conclusion

UFP Technologies is in an intact upward trend and currently shows bullish momentum. The zone around 250 USD is decisive:

• Above USD 250 → Trend acceleration
• Below 243 USD → Short-term weakness

You can see why we are talking about a points king here from the Traderfox rating.

A large proportion of the turnover of $UFPT (+1,91 %) is generated by key accounts. Here in particular $SYK (-1,22 %) and $ISRG (-1,32 %) . This can be positive, as the two companies appear healthy and dominate the market. However, it is also a bit of a cluster. How do you assess the constellation and what are your forecasts for UFP?

Hello my dears,

As promised, I'll start the new year with a look back and a brief analysis of the year 2025.

I am always happy to receive suggestions for improvement and ideas.

In the 5-year chart you can see an outperformance against popular and strong ETFs.

You can see the resulting higher volatility

Apart from 1% Bitcoin ETP, my portfolio consists exclusively of individual stocks.

I do not trade in certificates.

In the 2025 chartwe see a synchronization with the ETFs until the April crash.

In April, I was lucky enough to receive cash from my former employer. And so I was also able to take advantage of the price reduction 🍊.

Perhaps as a result of clever additional purchases and new purchases, there was a good outperformance compared to the ETFs.

In August, there were good figures for some companies (apart from Elf and Chipotle).

In addition, however, I spent a little more time with momentum stocks in the summer @Krush82 . In the end, I filtered out momentum stocks with good fundamental figures.

Something like

-Gilat $GILT (+8,4 %)

-AeroViroment $AVAV (+11,55 %)

When 🍊had once again pushed down the pharma sector, there was an additional purchase at

• Krystel $KRYS (+0,97 %)

Good figures for

• Micron $MU (+4,29 %) and SK Hynix $HY9H (+2,65 %)

and a new entry due to good momentum at

• Frequency $FEIM (+11,79 %)

then gave me a small year-end rally.

Flops 2025

But of course not everything is positive on the stock market.

And there are also rotten potatoes in a broadly diversified portfolio.

In contrast to an ETF, I have the option of sorting out the rotten potatoes in my portfolio. Which should ultimately lead to outperformance.

But sorting them out is not that easy.

Because some of the underperformers in 2026, such as

• Chipotle $CMG (-1,04 %)
• Constel Software $CSU (+0,45 %)
• Copart $CPRT (-0,93 %)
• Tetra Tech $TTEK (+0,03 %)
• UFP Tech $UFPT (+1,91 %)
• FICO $FICO (+1,04 %)
• Apollo Global $APO (+0,26 %)
• Ferrari $RACE (-0,8 %)

are less speculative quality stocks, which should actually hedge my portfolio.

My dears, I need your help here. help.

Which values would you stick to and where do you see a comeback?

My analysis would be:

• Eleven Beauty as a growth stock still has potential, and has been quite impacted by the China tariffs
• Chipotle continues to expand and grow.
• Constel. Software is a long term compounder which has suffered from CEO resignation and AI uncertainty. See a recovery here.
• FICO the monopoly has been partially broken. But still sees a moat.
• Copart, has been a steady performer so far. But difficult to assess how autonomous mobility will affect the business model. (eternal Selling)
• Ferrarisimilar to Copart. Is facing a major transformation with challenges (eternal sale). Sell)
• Tetra Tech, profiteer of AI and expansion of data centers. Tainted by the Trump administration. Because some public contracts in developing countries. But should benefit from climate change and may even be an insider tip in the election year.
• UFP Technology Growth sector with a moat. Fundamental figures are right, expect comeback (eternal). Buy later)
• Defi Technology the child has fallen into the well 😭. Eternal comeback due to rising Bitcoin.

Tops 2026

I continue to hold on to almost all stocks here.

I am particularly positive about the biotech sector.

• Krystel Biotech

• Applovin is now performing very well for the second year in a row. And some analysts also count the share among the favorites for 2026. @Semos25

• micron and sk Hynix were completely ignored by investors for a very long time despite their favorable valuations. I bought more shares several times during this period. Both shares are also among the favorites and AI profiteers in 2026

• Frequency moat in the niche. Profiteers from rising interest in quantum technology. Could benefit from the Spaxe X IPO and NASA's plan to travel to the moon.

• Kraken Robotichas been written about a lot in the last few days (thanks @Klein-Anleger ). I remain invested.

• Sofi, IES Holding, I remain invested.

• Palfingersurprise of the year, fundamentals fit, good dividend yield, profiteer from expansion in renewable energy, increase in defense spending. Chart-technically in a very exciting situation, hanging on to the old high. Watch and help @TomTurboInvest (Watch / Sell).

Let's wait and see whether investors will soon realize this. And perhaps Buffet or a star investor @Simpson gets involved in some companies.

Dear all, what are your value stocks?

$CPRT (-0,93 %)

The key figure with the highest stability for the Copart share is the reported profit, which is used below for the valuation. The P/E ratio (price/earnings ratio) calculated from this figure is 25.17, which is 1.79 points below the historical average of 26.96 for the last 10 years. From this perspective, the Copart share appears to be favorably valued.

The fair value of the Copart share is calculated over the 10-year valuation period selected above. The average P/E ratio in this case is 26.96.

Multiplied by the reported earnings per share of USD 1.59 over the last 4 quarters, this results in a fair value of USD 42.87 for the Copart share. The current share price of USD 40.51 is 5.5% below this fair value, which means that the share appears to be slightly undervalued.

$CMG (-1,04 %)

The key figure with the highest stability for Chipotle Mexican Grill shares is the operating cash flow, which is used below for the valuation. The KCV (price/cash flow ratio) calculated from this figure is 18.48, which is 12.01 points below the historical average of 30.49 for the last 10 years. From this perspective, the Chipotle Mexican Grill share appears to be favorably valued.

The fair value of the Chipotle Mexican Grill share is calculated over the 10-year valuation period selected above. The average KCV in this case is 30.49.

Multiplied by the operating cash flow per share of USD 1.65 over the last 4 quarters, this results in a fair value of USD 50.31 for the Chipotle Mexican Grill share. The current share price of USD 30.59 is 39.2% below this fair value, which corresponds to an undervaluation of the share.

$ELF (+7,53 %)

For the e.l.f. Beauty share, the most stable key figure is the adjusted profit. However, this should not be used for the valuation because the time series is too short for a representative average calculation. The operating cash flow is therefore used for the valuation. The KCV (price/cash flow ratio) calculated from this key figure is 26.51 and therefore 27.97 points below the historical average of 54.48 for the last 5 years. The e.l.f. Beauty share appears to be favorably valued from this perspective.

The calculation of the fair value of the e.l.f. Beauty share is calculated over the 5-year valuation period selected above. The average KCV in this case is 54.48.

Multiplied by the operating cash flow per share of USD 2.89 over the last 4 quarters, the fair value of the e.l.f. Beauty share has a fair value of USD 157.46. The current share price of USD 73.74 is 53.2% below this fair value, which corresponds to a strong undervaluation of the share.

$UFPT (+1,91 %)

The key figure with the highest stability for the UFP Technologies share is the adjusted profit, which is used below for the valuation. The P/E ratio (price/earnings ratio) calculated from this figure is 22.69, which is 0.72 points above the historical average of 21.97 for the last 10 years. From this perspective, the UFP Technologies share appears to be fairly valued.

The fair value of the UFP Technologies share is calculated over the 10-year valuation period selected above. The average P/E ratio in this case is 21.97.

Multiplied by the adjusted earnings per share of USD 9.82 over the last 4 quarters, this results in a fair value of USD 215.77 for the UFP Technologies share. The current share price of USD 226.11 is 4.8% above this fair value, which means that the share appears to be fairly valued.

$TTEK (+0,03 %)

The key figure with the highest stability for the Tetra Tech share is the adjusted profit, which is used below for the valuation. The P/E ratio (price/earnings ratio) calculated from this figure is 21.07, which is 2.74 points below the historical average of 23.81 for the last 10 years. From this perspective, the Tetra Tech share appears to be favorably valued.

The fair value of the Tetra Tech share is calculated over the 10-year valuation period selected above. The average P/E ratio in this case is 23.81.

Multiplied by the adjusted earnings per share of USD 1.52 over the last 4 quarters, this results in a fair value of USD 36.19 for the Tetra Tech share. The current share price of USD 32.22 is 11.0% below this fair value, which corresponds to an undervaluation of the share.

$MC (-0,53 %)

The key figure with the highest stability for the LVMH Moet Hennessy L.V. share is the operating cash flow, which is used below for the valuation. The KCV (price/cash flow ratio) calculated from this key figure is 15.32, which is 0.82 points below the historical average of 16.14 for the last 10 years. From this perspective, the LVMH Moet Hennessy L.V. share appears to be favorably valued.

The fair value of the LVMH Moet Hennessy L.V. share is calculated over the 10-year valuation period selected above. The average KCV in this case is 16.14.

Multiplied by the operating cash flow per share of EUR 39.16 over the last 4 quarters, this results in a fair value of EUR 632.04 for the LVMH Moet Hennessy L.V. share. The current share price of EUR 603.20 is 4.6% below this fair value, which means that the share appears to be fairly valued.

( Source share finder ).

$UFPT (+1,91 %) I also remain invested in this quality stock. I think the share price will be boosted by the star investor's new @Simpson will boost the share price.

UFP Technologies (UFPT ( Free Report ) reported earnings of $2.39 per share for the quarter, beating the Zacks' consensus estimate of $2.22 per share. In the prior-year quarter, earnings also amounted to USD 2.39 per share. The figures are adjusted for special effects.

This quarterly report shows a positive earnings surprise of 7.66%. In the previous quarter, a profit of USD 2.29 per share was expected for this packaging company and component manufacturer, but it actually achieved a profit of USD 2.50, which corresponds to a positive surprise of 9.17%.

In the last four quarters, the company has beaten consensus earnings per share estimates three times.

UFP, a company in the Zacks "Paper and Packaging Containers" industry, reported revenues of $154.56 million in the quarter ended September 2025, beating the Zacks Consensus Estimate by 3.55%. In the year-ago quarter, sales were $145.16 million. The company has beaten consensus estimates twice in the last four quarters.

https://www.zacks.com/stock/news/2784086/ufp-technologies-ufpt-beats-q3-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2784086